118 related articles for article (PubMed ID: 1206602)
1. Use of bufexamac suppositories in rectal conditions.
Samsi AB
J Postgrad Med; 1975 Jul; 21(3):131-4. PubMed ID: 1206602
[No Abstract] [Full Text] [Related]
2. [Results of a study of the resorption of bufexamac following rectal administration].
Glowania HJ; Hampl B
Z Hautkr; 1988 Mar; 63(3):211. PubMed ID: 3388925
[TBL] [Abstract][Full Text] [Related]
3. [Corticosteroid hormones in suppositories in the treatment of some diseases of the anorectal region].
Iukhbidova ZhM; Shkliar AS; Sergeev VV
Sov Med; 1973 Sep; 36(9):100-4. PubMed ID: 4756471
[No Abstract] [Full Text] [Related]
4. [Short-term treatment of "mobile" ano-rectal diseases].
Herr T
Z Allgemeinmed; 1969 Sep; 45(26):1214-5. PubMed ID: 5374620
[No Abstract] [Full Text] [Related]
5. [Clinical experience with JO 475 suppositories].
Nora J; Caroli J
Med Chir Dig; 1975; 4(1):67-9. PubMed ID: 1160428
[No Abstract] [Full Text] [Related]
6. [A new medicine in proctology: the procto-glyvenol (author's transl)].
Berson I; Geiser JD
Schweiz Rundsch Med Prax; 1975 Jan; 64(1):19-22. PubMed ID: 1089251
[No Abstract] [Full Text] [Related]
7. [Multicentric study with the corticoid-free anti-hemorrhoid drug Factu].
Brandes H
ZFA (Stuttgart); 1980 Feb; 56(4):284-8. PubMed ID: 7368805
[No Abstract] [Full Text] [Related]
8. [Comparative testing of Kamillosan cream and steroidal (0.25% hydrocortisone, 0.75% fluocortin butyl ester) and non-steroidal (5% bufexamac) dermatologic agents in maintenance therapy of eczematous diseases].
Aertgeerts P; Albring M; Klaschka F; Nasemann T; Patzelt-Wenczler R; Rauhut K; Weigl B
Z Hautkr; 1985 Feb; 60(3):270-7. PubMed ID: 3158124
[TBL] [Abstract][Full Text] [Related]
9. [Value of a new therapeutic agent, diosmine, in proctology].
Peeters JP
Brux Med; 1973 Oct; 53(10):591-4. PubMed ID: 4761153
[No Abstract] [Full Text] [Related]
10. [A new non-steroid anti-inflammatory agent in therapy of osteoarthrosis].
Loizzi P
Clin Ter; 1980 Mar; 92(5):497-512. PubMed ID: 7004750
[No Abstract] [Full Text] [Related]
11. [Antiinflammatory treatment of hemorrhoids and anal fissures].
Seghezzi R; Ercoli A; Bordonaro L
Minerva Chir; 1968 Dec; 23(24):1296-306. PubMed ID: 5735149
[No Abstract] [Full Text] [Related]
12. [On management of the anal symptom complex].
Yppen H; Richthammer H; Steyrer K
Wien Klin Wochenschr; 1967 Feb; 79(7):131-2. PubMed ID: 5592596
[No Abstract] [Full Text] [Related]
13. [Clinical study of topically administered bufexamac in general practice].
Mathieu R
Schweiz Rundsch Med Prax; 1971 Nov; 60(47):1577-8. PubMed ID: 5140890
[No Abstract] [Full Text] [Related]
14. [Treatment of anus diseases with a corticoid-free drug combination].
Röseler P
ZFA (Stuttgart); 1977 May; 53(13):748-50. PubMed ID: 560091
[No Abstract] [Full Text] [Related]
15. [Contact allergies caused by bufexamac].
Geier J; Fuchs T
Med Klin (Munich); 1989 Jul; 84(7):333-8. PubMed ID: 2529420
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of bufexamac in symptomatic treatment of hemorrhoids: cooperative study].
Vigoni M
Brux Med; 1972 Oct; 52(10):735-9. PubMed ID: 4656195
[No Abstract] [Full Text] [Related]
17. Bufexamac crystals in synovial fluid analysis.
Moens CH; Moens D; Moens PH
Ann Rheum Dis; 1985 May; 44(5):357-8. PubMed ID: 4004369
[No Abstract] [Full Text] [Related]
18. [The treatment of fissure in ano in clinical practice].
Hellinger J
Z Arztl Fortbild (Jena); 1966 Apr; 60(8):474-6. PubMed ID: 5983575
[No Abstract] [Full Text] [Related]
19. Management of haemorrhoids and associated ano-rectal conditions.
Carden AB
Drugs; 1972; 4(1):75-80. PubMed ID: 4637576
[No Abstract] [Full Text] [Related]
20. Biodegradations of the hydroxamic acid group of p-n-butoxyphenylacethydroxamic acid (bufexamac) in various animal species.
Roncucci R; Simon MJ; Lambelin G; Buu-Hoï NP
Xenobiotica; 1971; 1(4):567-8. PubMed ID: 5164808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
